From the Guidelines
Antiarrhythmic medications are classified into five main classes based on their mechanism of action, including Class I, Class II, Class III, Class IV, and a miscellaneous class. The classification of antiarrhythmic medications is crucial in selecting the appropriate medication for a specific arrhythmia type, patient characteristics, and potential side effects of each agent 1.
Classification of Antiarrhythmic Medications
- Class I agents block sodium channels and are further divided into three subclasses:
- Class IA (quinidine, procainamide, disopyramide) which moderately slow conduction and prolong repolarization
- Class IB (lidocaine, mexiletine) which minimally slow conduction and shorten repolarization
- Class IC (flecainide, propafenone) which markedly slow conduction with minimal effect on repolarization
- Class II agents are beta-blockers (metoprolol, propranolol, atenolol, esmolol) that decrease sympathetic activity on the heart
- Class III agents (amiodarone, sotalol, dofetilide, ibutilide) block potassium channels, prolonging repolarization and the refractory period
- Class IV agents are calcium channel blockers (verapamil, diltiazem) that slow conduction through the AV node
- Miscellaneous class includes adenosine, which transiently blocks AV nodal conduction, and digoxin, which increases vagal tone and slows AV conduction
Understanding these classifications is essential for clinicians to select the most appropriate medication for their patients, taking into account the specific arrhythmia type, patient characteristics, and potential side effects of each agent 2, 3, 1.
It is also important to consider the potential proarrhythmic effects of antiarrhythmic medications, which can be classified into ventricular proarrhythmia, atrial proarrhythmia, and abnormalities of conduction or impulse formation 4.
In summary, the classification of antiarrhythmic medications into five main classes provides a framework for selecting the most appropriate medication for a specific arrhythmia type and patient characteristics.
From the FDA Drug Label
Amiodarone is generally considered a class III antiarrhythmic drug, but it possesses electrophysiologic characteristics of all four Vaughan Williams classes. Like class I drugs, amiodarone blocks sodium channels at rapid pacing frequencies, and like class II drugs, it exerts a noncompetitive antisympathetic action One of its main effects, with prolonged administration, is to lengthen the cardiac action potential, a class III effect. The negative chronotropic effect of amiodarone in nodal tissues is similar to the effect of class IV drugs.
The antiarrhythmic classes with examples are:
- Class I: blocks sodium channels, example: not explicitly mentioned in the label, but amiodarone has class I characteristics
- Class II: noncompetitive antisympathetic action, example: not explicitly mentioned in the label, but amiodarone has class II characteristics
- Class III: lengthens the cardiac action potential, example: amiodarone
- Class IV: negative chronotropic effect in nodal tissues, example: not explicitly mentioned in the label, but amiodarone has class IV characteristics 5
From the Research
Antiarrhythmic Classes
The antiarrhythmic classes can be categorized based on their mechanism of action. The main classes are:
- Class I: Sodium channel blockers, examples include quinidine, procainamide, and lidocaine 6, 7
- Class II: Beta blockers, examples include propranolol, metoprolol, and atenolol
- Class III: Potassium channel blockers, examples include amiodarone, sotalol, and dofetilide 6, 8
- Class IV: Calcium channel blockers, examples include verapamil and diltiazem
Examples of Antiarrhythmic Drugs
Some examples of antiarrhythmic drugs include:
- Amiodarone: used for ventricular tachycardia and atrial fibrillation 6, 8
- Sotalol: used for ventricular tachycardia and atrial fibrillation 6
- Dronedarone: used for atrial fibrillation and has been shown to be protective against ventricular arrhythmia 6
- Dofetilide: used for atrial fibrillation and has been shown to be protective against ventricular arrhythmia 6, 8
- Ranolazine: an antianginal agent that has been shown to be protective against ventricular arrhythmia 6